Suggested remit: To appraise the clinical and cost effectiveness of resmetirom and semaglutide within its marketing authorisation for treating liver fibrosis (without cirrhosis) caused by metabolic dysfunction-associated steatohepatitis (MASH).
 
Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process STA Standard
ID number 6458

Project Team

Project lead scopingta@nice.org.uk

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
09 July 2025 This evaluation will now go ahead as a Single Technology Appraisal (STA). This evaluation will only cover semaglutide for treating metabolic dysfunction-associated steatohepatitis with liver fibrosis. The evaluation will begin in early November 2025.
17 April 2025 - 20 May 2025 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6458
15 May 2025 NICE is currently consulting on the draft scope for the partial update of our Non-alcoholic fatty liver disease: assessment and management guideline (NG49). As part of this update, we will use the term ‘metabolic dysfunction-associated steatotic liver disease’ (MASLD) instead of ‘non-alcoholic fatty liver disease’ (NAFLD) in the title and throughout the guideline. See the in development page for more details about the draft scope consultation which closes on 01 June 2025 at 11:59pm.
17 April 2025 In progress. Scoping commencing
11 April 2025 This topic will now be progressed as a Multiple Technology Appraisal (MTA) alongside the following topic; Resmetirom for treating metabolic dysfunction-associated steatohepatitis with liver fibrosis [ID6529] The Invitation to Participate (ITP) will now be issued week commencing 07 July 2025 and the MTA title and ID number is: Resmetirom and semaglutide for treating metabolic dysfunction-associated steatohepatitis with liver fibrosis [ID6458]
12 December 2024 Referral
29 November 2023 Awaiting development. Status change linked to Topic Selection Decision being set to Selected
29 November 2023 Topic selection

For further information on our processes and methods, please see our CHTE processes and methods manual